Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of WCK 6777 (Ertapenem + Zidebactam) in Healthy Adults
NCT05645757Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zidebactam in bacterial infection (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Number of Serious Adverse Events Reported and 3 more. Started Apr 2023; status: completed.
02
Drugs
zidebactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05645757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645757.